Patents by Inventor Peter Ambrose Lander

Peter Ambrose Lander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for modulating FXR
    Patent number: 8106077
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: January 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M Warshawsky
  • Compounds and methods for modulating FX-receptors
    Patent number: 7863302
    Abstract: Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • FXR agonists
    Patent number: 7846960
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • FXR AGONISTS
    Publication number: 20090270460
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: October 29, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20090093524
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: April 9, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • Compounds and methods for treating dyslipidemia
    Patent number: 7470705
    Abstract: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: December 30, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Peter Ambrose Lander, Nathan Bryan Mantlo, Eva Maria Martin de la Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Compounds and Methods for Modulating Fx-Receptors
    Publication number: 20080306125
    Abstract: Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: February 2, 2007
    Publication date: December 11, 2008
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
    Patent number: 7250442
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: July 31, 2007
    Assignee: Eli Lilly and Company
    Inventors: Matthew Lee Brown, Timothy Alan Grese, Prabhakar Kondaji Jadhav, David Andrew Neel, Mitchell Irvin Steinberg, Peter Ambrose Lander
  • Compounds and methods for inhibiting MRP1
    Patent number: 7064131
    Abstract: The present invention relates to a compound of formula (I) which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: June 20, 2006
    Assignee: Eli Lilly and Company
    Inventors: Peter Ambrose Lander, Mark Christopher Lohman
  • Compounds and methods for inhibiting mrp1
    Publication number: 20040235880
    Abstract: The present invention relates to a compound of formula (I) which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: June 25, 2004
    Publication date: November 25, 2004
    Inventors: Peter Ambrose Lander, Mark Christopher Lohman
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Compounds and methods for inhibiting MRP1
    Publication number: 20040077675
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 22, 2004
    Inventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Screenivasara Vepachedu, Yongping Xie
  • Tricyclic compounds as MRP1-inhibitors
    Patent number: 6673809
    Abstract: The present invention relates to a compounds of formula I, wherein A is olefin, diol, or acetonide; which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: January 6, 2004
    Assignee: Eli Lilly and Company
    Inventors: Peter Ambrose Lander, Qiuping Wang, Sreenivasarao Vepachedu
  • Compounds and method for inhibiting MRP1
    Patent number: 6670373
    Abstract: The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: December 30, 2003
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Sreenivasarao Vepachedu, Yongping Xie
  • Tricyclic compounds as mrp1-inhibitors
    Publication number: 20030216425
    Abstract: 1
    Type: Application
    Filed: April 16, 2003
    Publication date: November 20, 2003
    Inventors: Peter Ambrose Lander, Quiping Wang, Sreenivasarao Vepachedu
  • Methods and compounds for inhibiting mrp1
    Publication number: 20030100576
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: May 21, 2002
    Publication date: May 29, 2003
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst